Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07219472 · ClinicalTrials.gov registry record · NA
Scrambler Therapy for Chemotherapy-Induced Peripheral Neuropathy
A NA study of Chemotherapy-induced Peripheral Neuropathy and CIPN - Chemotherapy-Induced Peripheral Neuropathy, sponsored by Case Comprehensive Cancer Center.
- Recruiting
- Registry status
- NA
- Development phase
- 90
- Enrollment target
- 1
- Study location
NCT07219472: Recruiting NA study of Chemotherapy-induced Peripheral Neuropathy and CIPN - Chemotherapy-Induced Peripheral Neuropathy, sponsored by Case Comprehensive Cancer Center.
NCT07219472 is a NA study of Chemotherapy-induced Peripheral Neuropathy and CIPN - Chemotherapy-Induced Peripheral Neuropathy that is actively recruiting participants, run by Case Comprehensive Cancer Center. The registered enrollment target is 90 participants, below the 135-participant average among 29 other Chemotherapy-induced Peripheral Neuropathy trials with a reported enrollment target (33% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07219472, a NA study of Chemotherapy-induced Peripheral Neuropathy and CIPN - Chemotherapy-Induced Peripheral Neuropathy, is actively recruiting participants, sponsored by Case Comprehensive Cancer Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 90 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study is for people who have a condition called chemotherapy-induced peripheral neuropathy (CIPN). This condition develops as a result of receiving medication(s) to treat cancer, particularly chemotherapy. CIPN is characterized by pain, numbness, tingling or burning sensations, typically in the hands and feet of people. These symptoms can lead to physical suffering, limited ability to perform daily activities, and low quality of life. One of the ways to treat CIPN is using a device called Scrambler Therapy. Scrambler Therapy was approved by the Food and Drug Administration (FDA) in 2009 as a treatment for CIPN. The treatment involves electrical signals passing through wires attached to parts of the body via adhesive tabs near where symptoms of CIPN are experienced. A standard treatment course consists of 10 daily sessions lasting about one hour each. The purpose of this study is to determine the effect of a 10-day course of Scrambler Therapy on symptoms of chemotherapy-induced peripheral neuropathy, day-to-day activities, overall quality of life, and use of pain medications. Participants will be randomly assigned to one of two groups. One group will receive Scrambler Therapy. The other group will not receive it. Participants will not know which group they were in until after treatment has completed. Participants in the group who did not receive Scrambler Therapy will have the opportunity to receive it after one month. Participants will be in this research study about 12 to 14 months.
Primary Outcome
Participant-reported pain is measured by the Severity of Neuropathic Symptoms, in which participants rank their pain on a scale of 0 (Not at All) to 10 (Severe). Higher scores indicate greater pain symptoms.
Conditions Studied
Interventions
- DEVICE Scrambler Therapy
- OTHER Sham/No Intervention
Study Locations (1)
Ohio
- Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2026-04 |
| Est. Completion | 2027-12 |
| Phase | NA |
What NCT07219472 shows while recruiting
NCT07219472 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 135-participant average among 29 other Chemotherapy-induced Peripheral Neuropathy trials with a reported enrollment target (33% lower).
The record links to 2 conditions, with Chemotherapy-induced Peripheral Neuropathy appearing as the primary indexed condition, and to 2 interventions - of which Scrambler Therapy is the first listed.
NCT07219472 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT07219472 about?
NCT07219472 is a clinical study titled "Scrambler Therapy for Chemotherapy-Induced Peripheral Neuropathy". This research study is for people who have a condition called chemotherapy-induced peripheral neuropathy (CIPN). This condition develops as a result of receiving medication(s) to treat cancer, particularly chemotherapy. CIPN is characterized by pain, numbness, tingling or burning sensations, typical...
What is the current status of trial NCT07219472?
This trial is currently recruiting. It is a NA study. The enrollment target is 90 participants. The study started on 2026-04. Estimated completion is 2027-12.
What conditions does trial NCT07219472 study?
This clinical trial studies the following conditions: Chemotherapy-induced Peripheral Neuropathy, CIPN - Chemotherapy-Induced Peripheral Neuropathy.
What interventions are being tested in trial NCT07219472?
The interventions under investigation include: Scrambler Therapy (DEVICE), Sham/No Intervention (OTHER).
Who is sponsoring clinical trial NCT07219472?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07219472 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chemotherapy-induced Peripheral Neuropathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07219472's enrollment target sits among peer trials
90 11th of 29 higher than 19 of 29 other Chemotherapy-induced Peripheral Neuropathy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chemotherapy-induced Peripheral Neuropathy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Cryocompression for CIPN
RECRUITING · NA
-
VGAIT for Chemotherapy-induced Peripheral Neuropathy
RECRUITING · NA
-
Light Therapy for Chemotherapy Induced Peripheral Neuropathy in Childhood Cancer Survivors
RECRUITING · NA
-
Remote Monitoring and Management of Chemotherapy Induced Peripheral Neuropathy
RECRUITING · NA
-
Cryocompression to Reduce Chemotherapy-induced Peripheral Neuropathy in Gynecologic Cancer - COHORT 2
RECRUITING · NA
-
Exploring the Benefit of Peripheral Nerve Stimulation in Treating Pain From Chemo-induced Peripheral Neuropathy: A Longitudinal Single Center Feasibility Study
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia